Phlexglobal, the developer of PhlexEview4, will deliver the solution via a private cloud in a ‘Software as a Service’ (SaaS) model.
According to the company, the solution will provide Rho’s clients with greater visibility and accessibility to essential documents, in addition to metrics regarding the "completeness and readiness of the TMF."
Laura Helms Reece, co-chief executive officer, Rho, commented, “Selecting an eTMF system was a strategically important decision for Rho that will allow us to add more value for our clients.”
According to a recent report by Industry Standard Research (ISR) the eTMF market is predicted to grow sizably over the next three years – with more than 50% of investigative sites expected to have access to a sponsor/CRO eTMF solution.
Andrew Schafer, president at ISR, told us the driving demand is "simply an evolution" of pharmaceutical and service providers to web-based applications.